Tertiary Care for Visual Developmental Disorders in Pre-school Children

Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University (Other)
Overall Status
Completed
CT.gov ID
NCT03251456
Collaborator
(none)
1,114
1
2
10.4
107.3

Study Details

Study Description

Brief Summary

Visual development disorders are major public health problems among children especially in China. How to find an effective and economic way to manage the larger number of children in China remains exploring. The national basic public health services of China offer visual acuity screening for preschool children for free every year. The aim of this study is to demonstrate the feasibility, cost-effective and the influence factors of compliance of tertiary care for visual developmental disorders in pre-school children after screening, and whether this disease management model is more effective and superior than the current medical care in china.

Condition or Disease Intervention/Treatment Phase
  • Other: Tertiary care
  • Other: Usual Care
N/A

Detailed Description

Visual development disorders including amblyopia , strabismus ,refractive error are an important public health problem among children, and the visual impairment caused by visual development disorders is lifelong and can be profound. Timely discovering and treatment of visual development disorders are significant for the recovering of visual function in children. The national basic public health services of China offer the basic visual acuity screening every year for free. In this study, the investigators try to explore the cost-effective and compliance of the national basic public health services based tertiary care model for the management of visual development disorders among preschool children. This Tertiary care based on disease management model among preschool children was conducted at Yudu county, Jiangxi province, in China. Preschool vision screening relied on the national basic public health services of China (refractive errors examined by the Retinomax autorefractor). Children who failed the screening were randomized into two groups, the intervention group: their parents will be informed and transferred to an ophthalmologist and optometrist at Ophthalmic Referral Center, receiving basic eye examination and therapy (visual corrected by glasses and periodic review); The control group: their parents will be informed and suggest them to take their children to the hospital for further examination by themselves.

Study Design

Study Type:
Interventional
Actual Enrollment :
1114 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Tertiary Care Based Visual Developmental Diseases Management Model Among Preschool Children in China: a Cluster Randomized Controlled Trial
Actual Study Start Date :
Aug 18, 2017
Actual Primary Completion Date :
Jun 30, 2018
Actual Study Completion Date :
Jun 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tertiary care

Other: Tertiary care
Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary.

Active Comparator: Usual care

Other: Usual Care
Inform the parents that there are abnormalities after eye disease screening of their children Inform the parents that they should take their children to the hospital for further consultation Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary.

Outcome Measures

Primary Outcome Measures

  1. The consultation rate in six month after the parents receiving the visual screening report [6 months]

    The consultation rate will be determined by the number of children who had visual screening abnormal actually go to hospital for consultation by telephone follow-up.

Secondary Outcome Measures

  1. The cost-effective of the tertiary care for visual developmental disorders [6 months]

    The cost of the disease management model will be determined by the cost per child when receiving the therapy including the travelling and medical fee, and the time they spent. And the clinical efficacy of the tertiary care for visual developmental disorders will be determined by whether or not the child receiving the appropriate therapy according to the clinical guideline.

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years to 7 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Patients who are aged 4-7 years and of Chinese citizen

  2. Who is willing to sign the consent form

  3. Children at the kindergarten will receiving the eye diseases screening of public health equalization programs in China, and there are abnormal findings after screening

Exclusion Criteria:
  1. Unwilling to sign the consent form

  2. Exiting eye diseases and already receiving therapies and follow up

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yudu Ganzhou Jiangxi China 342300

Sponsors and Collaborators

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

Investigators

  • Principal Investigator: Yizhi LIU, MD,PhD, Zhongshan Ophthalmic Center, Sun Yat-sen University
  • Study Director: Yangfa ZENG, MD,Master, Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yizhi Liu, Clinical Professor,director of Zhongshan Ophthalmic Center, Zhongshan Ophthalmic Center, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT03251456
Other Study ID Numbers:
  • SYSU-OPH-002
First Posted:
Aug 16, 2017
Last Update Posted:
Jun 20, 2019
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yizhi Liu, Clinical Professor,director of Zhongshan Ophthalmic Center, Zhongshan Ophthalmic Center, Sun Yat-sen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 20, 2019